Literature DB >> 26811867

Second surgery for recurrent glioblastoma: A concise overview of the current literature.

Nicola Montemurro1, Paolo Perrini2, Magdalena Olivares Blanco3, Riccardo Vannozzi2.   

Abstract

Optimal treatment for recurrent glioblastoma continues to evolve. Currently, however, there is no consensus in the literature on the role of reoperation in the management of these patients, as several studies provide evidence for a longer overall survival in selected patients with recurrent glioblastoma who underwent second surgery and other studies report a limited impact of second surgery in the clinical course. In this paper, a review of the current literature was performed to analyze the role of reoperation in patients with recurrent glioblastoma and to report the overall survival from diagnosis, progression-free survival and quality of life. Using PubMed and Ovid Medline databases, we performed a review of the literature of the last seven years, finding a total of 28 studies and 2279 patients who underwent second surgery, that were included in the final analysis. The median overall survival from diagnosis and the median survival from second surgery were 18.5 months and 9.7 months, respectively. Extent of resection at reoperation improves overall survival, even in patients with subtotal resection at initial operation. Preoperative performance status and age are important predictors of a longer survival, reason why younger patients with a good preoperative performance status could benefit from reoperation.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glioblastoma; Overall survival; Progression-free survival; Recurrent glioblastoma; Reoperation

Mesh:

Year:  2016        PMID: 26811867     DOI: 10.1016/j.clineuro.2016.01.010

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  23 in total

1.  Survival outcomes following repeat surgery for recurrent glioblastoma: a single-center retrospective analysis.

Authors:  Paolo Perrini; Carlo Gambacciani; Alessandro Weiss; Francesco Pasqualetti; Durim Delishaj; Fabiola Paiar; Riccardo Morganti; Riccardo Vannozzi; Lodovico Lutzemberger
Journal:  J Neurooncol       Date:  2016-11-14       Impact factor: 4.130

2.  Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.

Authors:  Kunal S Patel; Richard G Everson; Jingwen Yao; Catalina Raymond; Jodi Goldman; Jacob Schlossman; Joseph Tsung; Caleb Tan; Whitney B Pope; Matthew S Ji; Nhung T Nguyen; Albert Lai; Phioanh L Nghiemphu; Linda M Liau; Timothy F Cloughesy; Benjamin M Ellingson
Journal:  Neurosurgery       Date:  2020-10-15       Impact factor: 4.654

3.  Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine.

Authors:  Katharina J Wenger; Marlies Wagner; Se-Jong You; Kea Franz; Patrick N Harter; Michael C Burger; Martin Voss; Michael W Ronellenfitsch; Emmanouil Fokas; Joachim P Steinbach; Oliver Bähr
Journal:  Oncol Lett       Date:  2017-05-25       Impact factor: 2.967

4.  Impact of recurrence pattern in patients undergoing a second surgery for recurrent glioblastoma.

Authors:  Francesco Pasqualetti; Nicola Montemurro; Isacco Desideri; Mauro Loi; Noemi Giannini; Giovanni Gadducci; Giulia Malfatti; Martina Cantarella; Alessandra Gonnelli; Sabrina Montrone; Luca Visani; Cristian Scatena; Antonio Giuseppe Naccarato; Paolo Perrini; Carlo Gambacciani; Orazio Santonocito; Riccardo Morganti; Fabiola Paiar
Journal:  Acta Neurol Belg       Date:  2021-08-16       Impact factor: 2.396

5.  Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of neuropathology in the management of progressive glioblastoma in adults.

Authors:  Abigail L Goodman; José E Velázquez Vega; Chad Glenn; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2022-06-01       Impact factor: 4.130

6.  Hyperintense signal on diffusion-weighted imaging for monitoring the acute response and local recurrence after photodynamic therapy in malignant gliomas.

Authors:  Yuichi Fujita; Hiroaki Nagashima; Kazuhiro Tanaka; Mitsuru Hashiguchi; Tomoo Itoh; Takashi Sasayama
Journal:  J Neurooncol       Date:  2021-09-22       Impact factor: 4.130

7.  CT-guided interstitial HDR-brachytherapy for recurrent glioblastoma multiforme: a 20-year single-institute experience.

Authors:  Georgios Chatzikonstantinou; Nikolaos Zamboglou; Eleftherios Archavlis; Iosif Strouthos; Eleni Zoga; Natasha Milickovic; Basil Hilaris; Dimos Baltas; Claus Rödel; Nikolaos Tselis
Journal:  Strahlenther Onkol       Date:  2018-09-10       Impact factor: 3.621

8.  Histopathologic quantification of viable tumor versus treatment effect in surgically resected recurrent glioblastoma.

Authors:  Stephen J Bagley; Robert D Schwab; Ernest Nelson; Angela N Viaene; Zev A Binder; Robert A Lustig; Donald M O'Rourke; Steven Brem; Arati S Desai; MacLean P Nasrallah
Journal:  J Neurooncol       Date:  2018-11-16       Impact factor: 4.130

Review 9.  Clinical and immunological correlates of long term survival in glioblastoma.

Authors:  Bartosz Czapski; Szymon Baluszek; Christel Herold-Mende; Bozena Kaminska
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

10.  Isolation of Circulating Tumour Cells in Patients With Glioblastoma Using Spiral Microfluidic Technology - A Pilot Study.

Authors:  Juliana Müller Bark; Arutha Kulasinghe; Gunter Hartel; Paul Leo; Majid Ebrahimi Warkiani; Rosalind L Jeffree; Benjamin Chua; Bryan W Day; Chamindie Punyadeera
Journal:  Front Oncol       Date:  2021-06-03       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.